Early Interventional Treatment with Intranasal Mometasone Furoate in Japanese Cedar/Cypress Pollinosis: A Randomized Placebo-Controlled Trial

Background: Little is known about the safety and effectiveness of early interventional treatment (EIT) with intranasal corticosteroids for seasonal allergic rhinitis. We designed a double-blinded, randomized, placebo-controlled 12-week trial of EIT with mometasone furoate nasal spray (MFNS) for Japa...

Full description

Bibliographic Details
Main Authors: Seiichiro Makihara, Mitsuhiro Okano, Tazuko Fujiwara, Masayo Kimura, Takaya Higaki, Takenori Haruna, Yohei Noda, Kengo Kanai, Shin Kariya, Kazunori Nishizaki
Format: Article
Language:English
Published: Elsevier 2012-01-01
Series:Allergology International
Subjects:
ECP
Online Access:http://www.sciencedirect.com/science/article/pii/S1323893015302239
id doaj-542293918de04a32b67b62e8ceab05d3
record_format Article
spelling doaj-542293918de04a32b67b62e8ceab05d32020-11-24T22:24:43ZengElsevierAllergology International1323-89302012-01-0161229530410.2332/allergolint.11-OA-0382Early Interventional Treatment with Intranasal Mometasone Furoate in Japanese Cedar/Cypress Pollinosis: A Randomized Placebo-Controlled TrialSeiichiro Makihara0Mitsuhiro Okano1Tazuko Fujiwara2Masayo Kimura3Takaya Higaki4Takenori Haruna5Yohei Noda6Kengo Kanai7Shin Kariya8Kazunori Nishizaki9Department of Otolaryngology-Head & Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.Department of Otolaryngology-Head & Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.Department of Otolaryngology-Head & Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.Department of Otolaryngology-Head & Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.Department of Otolaryngology-Head & Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.Department of Otolaryngology-Head & Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.Department of Otolaryngology-Head & Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.Department of Otolaryngology-Head & Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.Department of Otolaryngology-Head & Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.Department of Otolaryngology-Head & Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.Background: Little is known about the safety and effectiveness of early interventional treatment (EIT) with intranasal corticosteroids for seasonal allergic rhinitis. We designed a double-blinded, randomized, placebo-controlled 12-week trial of EIT with mometasone furoate nasal spray (MFNS) for Japanese cedar/cypress pollinosis (JCCP). Methods: A total of 50 JCCP patients received MFNS (200 ^g once daily: n = 25) or placebo (n = 25) starting on February 1, 2010. Treatments continued until the end of April. The primary endpoint was the comparison of the total nasal symptom score (TNSS) between the MFNS and placebo groups. The secondary endpoints included comparisons of QOL, daytime sleepiness, nasal ECP levels, and safety. Results: Continuous dispersion of Japanese cedar pollen began on February 22. Although the placebo group showed a significant worsening of symptoms after the start of the continuous dispersion, no worsening occurred in the MFNS group. A significant difference in the TNSS between the two groups was seen starting at 4 weeks after the treatment. Similar results were seen for QOL and sleepiness. Nasal ECP levels in March were significantly lower in the MFNS group. A total of 56% of the MFNS group progressed to a persistent allergic rhinitis state in accordance with the ARIA classification, as opposed to 84% of the placebo group. MFNS was well tolerated, and the plasma cortisol concentrations were similar between the two groups. Conclusions: EIT with MFNS for JCCP is both safe and effective. This treatment can potentially lessen symptoms and help pollinosis patients remain in the intermittent state.http://www.sciencedirect.com/science/article/pii/S1323893015302239early interventional treatmentECPintranasal corticosteroidsJapanese cedar/cypress pollinosistotal nasal symptom score
collection DOAJ
language English
format Article
sources DOAJ
author Seiichiro Makihara
Mitsuhiro Okano
Tazuko Fujiwara
Masayo Kimura
Takaya Higaki
Takenori Haruna
Yohei Noda
Kengo Kanai
Shin Kariya
Kazunori Nishizaki
spellingShingle Seiichiro Makihara
Mitsuhiro Okano
Tazuko Fujiwara
Masayo Kimura
Takaya Higaki
Takenori Haruna
Yohei Noda
Kengo Kanai
Shin Kariya
Kazunori Nishizaki
Early Interventional Treatment with Intranasal Mometasone Furoate in Japanese Cedar/Cypress Pollinosis: A Randomized Placebo-Controlled Trial
Allergology International
early interventional treatment
ECP
intranasal corticosteroids
Japanese cedar/cypress pollinosis
total nasal symptom score
author_facet Seiichiro Makihara
Mitsuhiro Okano
Tazuko Fujiwara
Masayo Kimura
Takaya Higaki
Takenori Haruna
Yohei Noda
Kengo Kanai
Shin Kariya
Kazunori Nishizaki
author_sort Seiichiro Makihara
title Early Interventional Treatment with Intranasal Mometasone Furoate in Japanese Cedar/Cypress Pollinosis: A Randomized Placebo-Controlled Trial
title_short Early Interventional Treatment with Intranasal Mometasone Furoate in Japanese Cedar/Cypress Pollinosis: A Randomized Placebo-Controlled Trial
title_full Early Interventional Treatment with Intranasal Mometasone Furoate in Japanese Cedar/Cypress Pollinosis: A Randomized Placebo-Controlled Trial
title_fullStr Early Interventional Treatment with Intranasal Mometasone Furoate in Japanese Cedar/Cypress Pollinosis: A Randomized Placebo-Controlled Trial
title_full_unstemmed Early Interventional Treatment with Intranasal Mometasone Furoate in Japanese Cedar/Cypress Pollinosis: A Randomized Placebo-Controlled Trial
title_sort early interventional treatment with intranasal mometasone furoate in japanese cedar/cypress pollinosis: a randomized placebo-controlled trial
publisher Elsevier
series Allergology International
issn 1323-8930
publishDate 2012-01-01
description Background: Little is known about the safety and effectiveness of early interventional treatment (EIT) with intranasal corticosteroids for seasonal allergic rhinitis. We designed a double-blinded, randomized, placebo-controlled 12-week trial of EIT with mometasone furoate nasal spray (MFNS) for Japanese cedar/cypress pollinosis (JCCP). Methods: A total of 50 JCCP patients received MFNS (200 ^g once daily: n = 25) or placebo (n = 25) starting on February 1, 2010. Treatments continued until the end of April. The primary endpoint was the comparison of the total nasal symptom score (TNSS) between the MFNS and placebo groups. The secondary endpoints included comparisons of QOL, daytime sleepiness, nasal ECP levels, and safety. Results: Continuous dispersion of Japanese cedar pollen began on February 22. Although the placebo group showed a significant worsening of symptoms after the start of the continuous dispersion, no worsening occurred in the MFNS group. A significant difference in the TNSS between the two groups was seen starting at 4 weeks after the treatment. Similar results were seen for QOL and sleepiness. Nasal ECP levels in March were significantly lower in the MFNS group. A total of 56% of the MFNS group progressed to a persistent allergic rhinitis state in accordance with the ARIA classification, as opposed to 84% of the placebo group. MFNS was well tolerated, and the plasma cortisol concentrations were similar between the two groups. Conclusions: EIT with MFNS for JCCP is both safe and effective. This treatment can potentially lessen symptoms and help pollinosis patients remain in the intermittent state.
topic early interventional treatment
ECP
intranasal corticosteroids
Japanese cedar/cypress pollinosis
total nasal symptom score
url http://www.sciencedirect.com/science/article/pii/S1323893015302239
work_keys_str_mv AT seiichiromakihara earlyinterventionaltreatmentwithintranasalmometasonefuroateinjapanesecedarcypresspollinosisarandomizedplacebocontrolledtrial
AT mitsuhirookano earlyinterventionaltreatmentwithintranasalmometasonefuroateinjapanesecedarcypresspollinosisarandomizedplacebocontrolledtrial
AT tazukofujiwara earlyinterventionaltreatmentwithintranasalmometasonefuroateinjapanesecedarcypresspollinosisarandomizedplacebocontrolledtrial
AT masayokimura earlyinterventionaltreatmentwithintranasalmometasonefuroateinjapanesecedarcypresspollinosisarandomizedplacebocontrolledtrial
AT takayahigaki earlyinterventionaltreatmentwithintranasalmometasonefuroateinjapanesecedarcypresspollinosisarandomizedplacebocontrolledtrial
AT takenoriharuna earlyinterventionaltreatmentwithintranasalmometasonefuroateinjapanesecedarcypresspollinosisarandomizedplacebocontrolledtrial
AT yoheinoda earlyinterventionaltreatmentwithintranasalmometasonefuroateinjapanesecedarcypresspollinosisarandomizedplacebocontrolledtrial
AT kengokanai earlyinterventionaltreatmentwithintranasalmometasonefuroateinjapanesecedarcypresspollinosisarandomizedplacebocontrolledtrial
AT shinkariya earlyinterventionaltreatmentwithintranasalmometasonefuroateinjapanesecedarcypresspollinosisarandomizedplacebocontrolledtrial
AT kazunorinishizaki earlyinterventionaltreatmentwithintranasalmometasonefuroateinjapanesecedarcypresspollinosisarandomizedplacebocontrolledtrial
_version_ 1725760077889011712